Literature DB >> 760743

Clonidine withdrawal. Mechanism and frequency of rebound hypertension.

G G Geyskes, P Boer, E J Dorhout Mees.   

Abstract

1. The frequency and pathophysiology of the clonidine withdrawal syndrome was studied in fourteen hypertensive patients on chronic clonidine therapy. 2. After sudden cessation of clonidine (900 microgram daily) almost all of the patients showed an excessive increase of the heart rate and blood pressure. Seven of the fourteen patients had subjective symptoms, in three severe enough to require interruption of observation by therapeutic intervention 12 to 60 h after the last dose of clonidine. After clonidine withdrawal, NAE increased to abnormally high values in correlation with the blood pressure (P less than 0.01) and heart rate (P less than 0.001), whereas PRA even decreased initially, probably secondary to the rise of the blood pressure, and only rose, although not significantly, 48 h after withdrawal. PRA was not correlated with NAE, heart rate, or blood pressure. 3. It is concluded that the clonidine withdrawal phenomenon is a frequently occurring and potentially dangerous syndrome. Overactivity of the sympathetic nervous system is mainly responsible, without the mediation of the renin angiotensin system. This also explains our experience that adrenergic beta-receptor blocking drugs do not prevent the rise in BP, although they alleviate some of the symptoms.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 760743      PMCID: PMC1429594          DOI: 10.1111/j.1365-2125.1979.tb00897.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

Review 1.  Mechanisms regulating renin release.

Authors:  J O Davis; R H Freeman
Journal:  Physiol Rev       Date:  1976-01       Impact factor: 37.312

2.  Rapid clonidine withdrawal with blood pressure overshoot exaggerated by beta-blockade.

Authors:  R R Bailey; T J Neale
Journal:  Br Med J       Date:  1976-04-17

3.  A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines.

Authors:  A H ANTON; D F SAYRE
Journal:  J Pharmacol Exp Ther       Date:  1962-12       Impact factor: 4.030

4.  The over-shoot phenomenon on withdrawal of clonidine therapy.

Authors:  A D Goldberg; P R Wilkinson; E B Raftery
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

5.  Central nervous system actions of clonidine in hypertension.

Authors:  S W Hoobler; T Kashima
Journal:  Mayo Clin Proc       Date:  1977-06       Impact factor: 7.616

6.  Comparison of the renin response to dopamine and noradrenaline in normal subjects and patients with autonomic insufficiency.

Authors:  C S Wilcox; M J Aminoff; A B Kurtz; J D Slater
Journal:  Clin Sci Mol Med       Date:  1974-04

7.  Blood pressure crisis following withdrawal of clonidine (Catapres, Catapresan), with special reference to arterial and urinary catecholamine levels, and suggestions for acute management.

Authors:  L Hansson; S N Hunyor; S Julius; S W Hoobler
Journal:  Am Heart J       Date:  1973-05       Impact factor: 4.749

8.  Clonidine in the treatment of severe hypertension.

Authors:  J Raftos; G E Bauer; R G Lewis; G S Stokes; A S Mitchell; A A Young; I Maclachlan
Journal:  Med J Aust       Date:  1973-04-21       Impact factor: 7.738

9.  Effect of salt depletion and propranolol on blood pressure and plasma renin activity in various forms of hypertension.

Authors:  G G Geyskes; P Boer; J Vos; F H Leenen; E J Mees
Journal:  Circ Res       Date:  1975-06       Impact factor: 17.367

10.  Clonidine withdrawal in hypertension. Changes in blood-pressure and plasma and urinary noradrenaline.

Authors:  J L Reid; L M Wing; H J Dargie; C A Hamilton; D S Davies; C T Dollery
Journal:  Lancet       Date:  1977-06-04       Impact factor: 79.321

View more
  25 in total

1.  Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension.

Authors:  Michiel J B Kemme; Jeroen P vd Post; Rik C Schoemaker; Matthias Straub; Adam F Cohen; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

2.  Use of labetalol in hypertensive patients during discontinuation of clonidine therapy.

Authors:  T Rosenthal; B Rabinowitz; H Boichis; E Elazar; A Brauner; H N Neufeld
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

Review 3.  Radioligand binding studies of adrenergic receptors and their clinical relevance.

Authors:  P J Barnes
Journal:  Br Med J (Clin Res Ed)       Date:  1981-04-11

4.  ABC of blood pressure reduction.

Authors:  B A McGovern
Journal:  Br Med J (Clin Res Ed)       Date:  1981-04-11

5.  Reinforcing properties of clonidine in rhesus monkeys.

Authors:  W L Woolverton; W D Wessinger; R L Balster
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

6.  Clinical experience with guanfacine in long-term treatment of hypertension. Part II: adverse reactions to guanfacine.

Authors:  P Jerie
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

7.  Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects.

Authors:  Yahya Shehabi; Urban Ruettimann; Harriet Adamson; Richard Innes; Mathieu Ickeringill
Journal:  Intensive Care Med       Date:  2004-08-26       Impact factor: 17.440

8.  Drug withdrawal and rebound hypertension: differential action of the central antihypertensive drugs moxonidine and clonidine.

Authors:  H Rupp; B Maisch; C G Brilla
Journal:  Cardiovasc Drugs Ther       Date:  1996-06       Impact factor: 3.727

9.  Clonidine dependence in the guinea-pig isolated ileum.

Authors:  H O Collier; N J Cuthbert; D L Francis
Journal:  Br J Pharmacol       Date:  1981-06       Impact factor: 8.739

10.  Effect of chronic clonidine treatment on the turnover of noradrenaline and dopamine in various regions of the rat brain.

Authors:  L Rochette; A M Bralet; J Bralet
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-04       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.